Hereditary breast cancerNews & Research
15 curated articles for Hereditary breast cancer — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- International journal of women's health May 6, 2026
Willingness of Chinese Breast Cancer Patients for Their Children to Undergo BRCA1/2 Genetic Testing and Associated Factors.
Pathogenic variants in BRCA1/2 are important risk factors for breast cancer. However, little is known about whether Chinese breast cancer patients are willing for their children to undergo genetic testing. This study assessed patients' knowledge and attitudes toward genetic testing and risk manageme...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- NPJ breast cancer May 5, 2026
Co-occurring rare germline DNA repair gene variants in BRCA1/BRCA2 implicated hereditary breast cancer families.
As gene-panels expand to include candidate breast cancer predisposing genes (CPGs) involved in diverse DNA repair pathways, we investigated an index breast cancer (BC) case from 56 BRCA1/BRCA2 implicated high-risk hereditary BC families using gene-based approach for co-occurring, rare germline varia...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Familial cancer Apr 28, 2026
Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy.
Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy.
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Clinical breast cancer Apr 25, 2026
Uptake of Cascade Genetic Testing for Hereditary Breast Cancer in the Public Health System in a Middle-Income Country: A Real-World Study.
Hereditary breast cancer accounts for up to one-third of cases in Brazil. Cascade genetic testing is essential to identify at-risk relatives, yet uptake of cascade genetic testing remains low in most settings. This study aimed to evaluate referral and uptake of cascade genetic testing in a public un...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Cancer reports (Hoboken, N.J.) Apr 25, 2026
Altered Estrogen Receptor Signaling Pathway in BRCA2-Deficient Estrogen Receptor-Positive/HER2-Negative Breast Cancer.
Hereditary breast cancer accounts for approximately 10% of all breast cancer cases, with germline BRCA2 pathogenic variants (PVs) being the most prevalent genetic alteration. BRCA2 PVs predominantly lead to estrogen receptor (ER)-positive/HER2-negative breast cancers, which exhibit more aggressive p...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Maedica Apr 14, 2026
Genetic Testing in Breast Cancer: Narrative Review and Clinical Insights.
Identifying hereditary breast cancer is increasingly important, as germline pathogenic variants not only influence lifetime cancer risk but also guide surveillance, preventive strategies and targeted treatments. While breast cancer genes (BRCA1 and BRCA2) remain central to hereditary breast and ovar...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Seminars in oncology nursing Apr 2, 2026
Genomic Instability in Hereditary Breast Cancer: Clinical and Nursing Implications for Risk Assessment and Targeted Therapeutic Strategies.
This review aims to bridge genomic insights with oncology nursing practice, promoting risk-informed care for patients with hereditary breast cancer (HBC). This study reviewed publications from 2018 to 2024, searching PubMed, CINAHL, and Cochrane under PRISMA guidelines. It systematically reviews GI,...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Seminars in oncology nursing Apr 2, 2026
The Advanced Nurse Practitioner's Role in Hereditary Breast Cancer Clinics: A Patient-Centered Approach.
The demand for hereditary breast cancer genetic services is outpacing workforce capacity, creating barriers to timely diagnosis and prevention. This paper discusses the role of the Breast Advanced Nurse Practitioner (ANP) as a strategic solution to these challenges, focusing on how ANPs can deliver ...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- International journal of molecular sciences Mar 28, 2026
STK11 and DNA Repair Gene Mutations Define Hereditary Subset of Middle Eastern Papillary Thyroid Cancer.
Papillary thyroid cancer (PTC) is the most common endocrine malignancy with especially high incidence in Middle Eastern populations. While classical hereditary syndromes explain a minority of cases, the broader germline landscape of non-syndromic PTC remains unclear. Whole-exome sequencing was perfo...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Cancer investigation Mar 27, 2026
CHEK2 Germline Variants and Their Clinical Implications: Experience from a Turkish Hereditary Cancer Cohort.
CHEK2 is a moderate-penetrance tumor suppressor gene primarily linked to hereditary breast cancer, yet growing evidence implicates it in a wider tumor spectrum. Data from underrepresented populations, such as Türkiye, remains limited. We retrospectively analyzed 895 individuals referred for her...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Journal of the National Cancer Institute Mar 15, 2026
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes.
The association of germline pathogenic and likely pathogenic variants (GPVs) in hereditary breast cancer genes with underlying tumor biology and clinical outcomes remain incompletely understood. This study characterized differences in somatic alterations and intrinsic subtypes between sporadic and h...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Gland surgery Mar 11, 2026
Biological features and locoregional recurrence in early-onset breast cancer: insights from the Young Women's Breast Cancer Study and the Prospective Study of Outcomes in Sporadic and Hereditary Breast Cancer.
Biological features and locoregional recurrence in early-onset breast cancer: insights from the Young Women's Breast Cancer Study and the Prospective Study of Outcomes in Sporadic and Hereditary Breast Cancer.
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Breast cancer (Tokyo, Japan) Mar 7, 2026
Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers.
Long-term outcome on breast cancer surveillance in BRCA mutation carriers are limited, especially in Asian populations where uptake of preventive surgery is low. We conducted a retrospective cohort study of 722 female BRCA1 and BRCA2 mutation carriers enrolled between January 2007 and December 2024 ...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Annals of oncology : official journal of the European Society for Medical Oncology Feb 14, 2026
Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.
The clinical implications of specific pathogenic and likely pathogenic variant (LP/PV) types and locations in the BRCA1 orBRCA2 tumor-suppressor genes remain to be elucidated. The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, hospital-based, retrospective cohort study that i...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
- Annals of surgical oncology Feb 13, 2026
Germline BRCA1/2 Mutation Prevalence in Unselected ER-Low/HER2-Negative Breast Cancer.
Estrogen receptor (ER)-low breast cancers, defined as tumors with 1-10% ER expression, exhibit clinicopathologic and molecular features, as well as chemotherapy responses, resembling triple-negative breast cancer (TNBC), leading to updated guidelines. However, current BRCA1/2 testing guidelines clas...
Why it matters: Recent peer-reviewed research on Hereditary breast cancer that may be relevant for patients and caregivers.
More on Hereditary breast cancer
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.